title: Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
abstract: BACKGROUND
  Endometriosis is a benign gynecologic disease with a high prevalence. It is a multifactorial and polygenic entity in which the fibrinolytic system may be implicated. The objective of this study was to evaluate the plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in a group of women with and without endometriosis and to analyze the influence of this polymorphism in PAI-1 expression in endometrial tissue and peritoneal fluid.
  
  
  METHODS
  In 389 women (170 patients with endometriosis and 219 controls) PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. Quantitative real-time RT-PCR assay was used to quantify PAI-1 mRNA and PAI-1 antigen (ag) levels were quantified by ELISA.
  
  
  RESULTS
  The genotype and allele frequencies of PAI-1 4G/5G polymorphism did not differ significantly between patients and controls. Control women with the 4G/4G genotype had higher endometrial PAI-1ag (P=0.026) and mRNA (P=0.014) levels than those with the 5G/5G genotype. Control carrying the 4G/4G genotype tended to have higher peritoneal fluid PAI-1ag levels than those carrying the 5G/5G genotype. Moreover, PAI-1ag levels in peritoneal fluid were higher in patients than in controls (P=0.003).
  
  
  CONCLUSIONS
  The PAI-1 genotype distribution was similar in patients and controls. PAI-1 levels in endometrial tissue and peritoneal fluid seem to be associated with PAI-1 4G/5G polymorphism in controls. The increased PAI-1ag levels observed in peritoneal fluid from patients could contribute to increase the peritoneal adhesions observed in endometriosis.
authors.affiliation: Research Center, Hospital Universitario La Fe, Valencia, Spain.
authors.forename: Luis A
authors.initials: LA
authors.lastname: Ramón
authors.forename: Juan
authors.initials: J
authors.lastname: Gilabert-Estellés
authors.forename: Raul
authors.initials: R
authors.lastname: Cosín
authors.forename: Juan
authors.initials: J
authors.lastname: Gilabert
authors.forename: Francisco
authors.initials: F
authors.lastname: España
authors.forename: Remedios
authors.initials: R
authors.lastname: Castelló
authors.forename: Melitina
authors.initials: M
authors.lastname: Chirivella
authors.forename: Alberto
authors.initials: A
authors.lastname: Romeu
authors.forename: Amparo
authors.initials: A
authors.lastname: Estellés
mesh_terms: D000293:Adolescent; D000328:Adult; D001202:Ascitic Fluid / Q000737:chemistry; D004715:Endometriosis / Q000209:etiology / Q000235:genetics* / Q000378:metabolism; D004717:Endometrium / Q000737:chemistry; D005260:Female; D006801:Humans; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000235:genetics*; D011110:Polymorphism, Genetic; D012333:RNA, Messenger / Q000032:analysis*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger